# Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

> **NCT07174349** · PHASE4 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 20 (estimated)

## Conditions studied

- Urinary Retention Postoperative

## Interventions

- **DRUG:** Uroselective alpha-1-adrenergic receptor antagonist
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07174349
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174349, "Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07174349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*